Clinical Study on the Effect of Digital Human Intelligent Teaching of Baduanjin on Cardiac Rehabilitation in Patients with Chronic Heart Failure

注册号:

Registration number:

ITMCTR2025001031

最近更新日期:

Date of Last Refreshed on:

2025-05-26

注册时间:

Date of Registration:

2025-05-26

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

八段锦数字人智能教学对慢性心力衰竭患者心脏康复的临床研究

Public title:

Clinical Study on the Effect of Digital Human Intelligent Teaching of Baduanjin on Cardiac Rehabilitation in Patients with Chronic Heart Failure

注册题目简写:

English Acronym:

研究课题的正式科学名称:

八段锦数字人智能教学对慢性心力衰竭患者心脏康复的临床研究

Scientific title:

Clinical Study on the Effect of Digital Human Intelligent Teaching of Baduanjin on Cardiac Rehabilitation in Patients with Chronic Heart Failure

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

彭天洁

研究负责人:

仇盛蕾

Applicant:

TianJie Peng

Study leader:

ShengLei Qiu

申请注册联系人电话:

Applicant telephone:

13340716678

研究负责人电话:

Study leader's telephone:

13426241268

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

tianjiepeng2024@163.com

研究负责人电子邮件:

Study leader's E-mail:

choushenglei@bjzhongyi.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市东城区美术馆后街23号

研究负责人通讯地址:

北京市东城区美术馆后街23号

Applicant address:

23 Meishuguan Hou Jie Dongcheng District Beijing China

Study leader's address:

23 Meishuguan Hou Jie Dongcheng District Beijing China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京中医医院

Applicant's institution:

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025BL02-028-02

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

首都医科大学附属北京中医医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025/4/22 0:00:00

伦理委员会联系人:

刘声

Contact Name of the ethic committee:

010-87906734

伦理委员会联系地址:

北京市东城区美术馆后街69号北京中医医院景美办公楼113

Contact Address of the ethic committee:

Room 113 Jingmei Office Building Beijing Traditional Chinese Medicine Hospital69 Back Street Art Museum Dongcheng District Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8790 6734

伦理委员会联系人邮箱:

Contact email of the ethic committee:

liusheng4377@163.com

研究实施负责(组长)单位:

首都医科大学附属北京中医医院

Primary sponsor:

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

研究实施负责(组长)单位地址:

北京市东城区美术馆后街23号

Primary sponsor's address:

23 Meishuguan Hou Jie Dongcheng District Beijing China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

东城区

Country:

China

Province:

Beijing

City:

Dongcheng District

单位(医院):

首都医科大学附属北京中医医院

具体地址:

北京市东城区美术馆后街23号

Institution
hospital:

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

Address:

23 Meishuguan Hou Jie Dongcheng District Beijing China

经费或物资来源:

河北省中医药管理局

Source(s) of funding:

Hebei Provincial Administration of Traditional Chinese Medicine

研究疾病:

慢性心力衰竭

研究疾病代码:

Target disease:

Chronic Heart Failure(CHF)

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

应用八段锦数字人智能教学为CHF患者制定个体化康复处方,通过过程监测、任务评估、综合管理,初步制定CHF普适性中医康复处方。

Objectives of Study:

Utilize the intelligent teaching of the Baduanjin digital human to develop individualized rehabilitation prescriptions for CHF (Chronic Heart Failure) patients. Through process monitoring, task evaluation, and comprehensive management, an initial universal TCM (Traditional Chinese Medicine) rehabilitation prescription for CHF will be formulated.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

同时具备以下条件者方可入选: (1)年龄40-75岁 ; (2)西医诊断为慢性心力衰竭者; (3)中医辨证为气虚血瘀证患者; (4)心功能NYHA II-III 级; (5)目前参加体育锻炼时间少于每周60分钟; (6)签署知情同意书。

Inclusion criteria

Inclusion Criteria: (1) Age between 40 and 75 years; (2) Diagnosed with chronic heart failure (CHF) according to Western medicine criteria; (3) Identified as having a Qi deficiency and blood stasis syndrome according to Traditional Chinese Medicine (TCM) diagnosis; (4) Cardiac function classified as NYHA II-III; (5) Currently engaged in physical exercise for less than 60 minutes per week; (6) Signed informed consent form.

排除标准:

(1) 四肢活动受限; (2) 血压控制不佳的高血压患者(收缩压≥180mmHg 或舒张压≥100mmHg); (3) 慢性心力衰竭急性发作期; (4) 静息心率超过每分钟100次,或有患有严重的心律失常(心房颤动伴快速心室率,心室颤动、室性心动过速等); (5) 存在心肺运动试验或运动训练方案绝对禁忌证; (6) 患有严重感染、慢性阻塞性疾病、呼吸衰竭或肺心病等; (7) 有严重的原发性肝、肾或血液系统疾病或患有严重的精神疾病或无法控制的全身性疾病; (8) 合并严重的代谢性疾病(如甲状腺毒症、糖尿病酮症); (9) 正在接受康复运动疗法,其中包括传统中医导引术训练(如八段锦、易筋经、五禽戏等)。 符合以上任意一项者,排除入选。

Exclusion criteria:

(1) Restricted limb mobility; (2) Hypertensive patients with poorly controlled blood pressure (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg); (3) Acute exacerbation of chronic heart failure; (4) Resting heart rate exceeding 100 beats per minute or presence of severe arrhythmias (atrial fibrillation with rapid ventricular rate ventricular fibrillation ventricular tachycardia etc.); (5) Absolute contraindications for cardiopulmonary exercise testing or exercise training programs; (6) Severe infections chronic obstructive pulmonary disease respiratory failure or cor pulmonale; (7) Severe primary hepatic renal or hematological diseases or severe psychiatric disorders or uncontrolled systemic diseases; (8) Comorbid severe metabolic disorders (e.g. thyrotoxicosis diabetic ketoacidosis); (9) Currently undergoing rehabilitation exercise therapy including traditional Chinese Daoyin training (e.g. Baduanjin Yijinjing Wuqinxi etc.). Participants meeting any of the above criteria will be excluded.

研究实施时间:

Study execute time:

From 2025-01-01

To      2026-12-31

征募观察对象时间:

Recruiting time:

From 2025-06-01

To      2026-09-30

干预措施:

Interventions:

组别:

对照组

样本量:

35

Group:

Control Group

Sample size:

干预措施:

在西医规范治疗基础上(参考《中国心力衰竭诊断和治疗指南2024》)进行中等强度有氧步行(参考《慢性心力衰竭心脏康复中国专家共识》)。

干预措施代码:

Intervention:

Implement moderate-intensity aerobic walking in combination with standard Western medicine treatment (referencing the China Heart Failure Diagnosis and Treatment Guidelines 2024) guided by the Chinese Expert Consensus on Cardiac Rehabilitation for Chronic Heart Failure.

Intervention code:

组别:

试验组

样本量:

35

Group:

Intervention Group

Sample size:

干预措施:

在西医规范治疗基础上(参考《中国心力衰竭诊断和治疗指南2024》)进行八段锦数字人智能教学康复锻炼。

干预措施代码:

Intervention:

On the basis of standardized Western medical treatment (referencing the China Heart Failure Diagnosis and Treatment Guidelines 2024), Baduanjin AI-powered digital teaching system will be implemented for rehabilitation exercise.

Intervention code:

样本总量 Total sample size : 70

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京市

市(区县):

东城区

Country:

China

Province:

Beijing

City:

Dongcheng District

单位(医院):

首都医科大学附属北京中医医院

单位级别:

三级甲等中医医院

Institution/hospital:

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

Level of the institution:

Class A Grade 3 Traditional Chinese Medicine Hospital

国家:

中国

省(直辖市):

北京市

市(区县):

朝阳区

Country:

China

Province:

Beijing

City:

Chaoyang District

单位(医院):

北京市朝阳区常营社区卫生服务中心

单位级别:

基层医疗卫生机构

Institution/hospital:

the Sanitary Service Center of Changying Community in Chaoyang District Beijing

Level of the institution:

Grassroots Medical and Health Institutions

国家:

中国

省(直辖市):

北京市

市(区县):

顺义区

Country:

China

Province:

Beijing

City:

Shunyi District

单位(医院):

北京中医医院顺义医院

单位级别:

三级甲等中医医院

Institution/hospital:

Beijing Traditional Chinese Medicine Hospital Shunyi Hospital

Level of the institution:

Class A Grade 3 Traditional Chinese Medicine Hospital

国家:

中国

省(直辖市):

河北省

市(区县):

邯郸市

Country:

China

Province:

Hebei Province

City:

Handan City

单位(医院):

邯郸市中医院

单位级别:

三级甲等中医医院

Institution/hospital:

Handan Traditional Chinese Medicine Hospital

Level of the institution:

Class A Grade 3 Traditional Chinese Medicine Hospital

测量指标:

Outcomes:

指标中文名:

左心室射血分数

指标类型:

次要指标

Outcome:

Left Ventricular Ejection Fraction(LVEF)

Type:

Secondary indicator

测量时间点:

测量方法:

心脏超声

Measure time point of outcome:

Measure method:

Echocardiography

指标中文名:

最大代谢当量(METs)

指标类型:

次要指标

Outcome:

Metabolic Equivalent of Task

Type:

Secondary indicator

测量时间点:

测量方法:

心肺运动试验

Measure time point of outcome:

Measure method:

Cardiopulmonary Exercise Testing (CPET)

指标中文名:

中医证候

指标类型:

次要指标

Outcome:

Traditional Chinese Medicine Syndrome Score (TCMSS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

N末端B型利钠肽前体

指标类型:

次要指标

Outcome:

NT-proBNP(N-terminal pro-B-type Natriuretic Peptide)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平衡能力测试

指标类型:

次要指标

Outcome:

Balance Assessment(BA)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

明尼苏达生活量表

指标类型:

主要指标

Outcome:

Minnesota Living with Heart Failure Questionnaire scores

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂水平

指标类型:

次要指标

Outcome:

Blood Lipid Levels

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心脏代谢指数

指标类型:

次要指标

Outcome:

Cardiometabolic Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

通气无氧阈

指标类型:

次要指标

Outcome:

Ventilatory Anaerobic Threshold

Type:

Secondary indicator

测量时间点:

测量方法:

心肺运动试验

Measure time point of outcome:

Measure method:

Cardiopulmonary Exercise Testing (CPET)

指标中文名:

六分钟步行试验

指标类型:

次要指标

Outcome:

Six-Minute Walk Test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

90天再住院率

指标类型:

主要指标

Outcome:

90-day Readmission Rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高敏C反应蛋白

指标类型:

次要指标

Outcome:

High-Sensitivity C-Reactive Protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

最大摄氧量

指标类型:

次要指标

Outcome:

Maximal Oxygen Uptake

Type:

Secondary indicator

测量时间点:

测量方法:

心肺运动试验

Measure time point of outcome:

Measure method:

Cardiopulmonary Exercise Testing (CPET)

指标中文名:

心率变异性

指标类型:

次要指标

Outcome:

Heart Rate Variability

Type:

Secondary indicator

测量时间点:

测量方法:

动态心电图

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 40
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用计算机随机数字法(SAS 9.4软件)生成包含70个受试者的随机化序列,按1:1比例实施平行分组设计,将受试者分配至试验组和对照组。为保障分配隐藏,随机序列由独立于研究团队的操作人员密封于编号不透明信封中。当受试者完成知情同意并满足全部纳入标准后,临床研究协调员将按序拆封对应信封完成分组操作。

Randomization Procedure (please state who generates the random number sequence and by what method):

The subjects were assigned to the intervention group and the control group with a 1:1 ratio by utilizing a table of random numbers which is generated by SAS 9.4 software. To ensure allocation concealment the random sequence is sealed in numbered opaque envelopes by an independent operators out of the research team. The clinical study coordinator will open the corresponding envelopes to complete the grouping operation only after the subjects have completed informed consent and met all inclusion criteria.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw Data Will Not Be Shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above